Gamma interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte/monocyte colony formation by unknown
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T  lymphocytes exert both stimulatory and suppressive effects that regulate the 
activity of immune cells. Recent evidence suggests that they may also play a role 
in regulating growth and differentiation of other types of hematopoietic cells. T 
cells have been observed to enhance  proliferation  and differentiation  of pluri- 
potent (1,2) as well as committed precursors from several different hematopoietic 
cell types through  release of soluble factors (3-6).  In addition, abnormalities in 
the  numbers  or  state  of activation  of T  cells  are  sometimes  associated  with 
inhibition of bematopoiesis. For example, certain cases of T  cell chronic lympho- 
cytic leukemia are associated with anemia or neutropenia  (7-9), and  increased 
numbers of activated T  lymphocytes are found in the peripheral blood or bone 
marrow  of patients  with  hematopoietic  disorders such as aplastic  anemia  (10- 
12),  Felty's  syndrome  (13,  14)  or  isolated  neutropenia  (15).  In  vitro  colony 
formation  by myeloid or  erytbroid  precursor  cells from  the  bone  marrow  of 
these patients is decreased.  However, normal colony formation can be restored 
if bone  marrow  preparations  are  depleted  of T  cells (1 1,  16,  17).  Moreover, 
colony formation by bone marrow cells from healthy donors is suppressed by the 
addition of patients' T  cells, but not by T  cells from healthy donors (12,  13,  16, 
18,  19).  Although  the  methods  used to remove T  lymphocytes in some of the 
discussed experiments also remove NK cells, which can mediate colony-inhibiting 
activity (20-22),  a  role  for T  ceils in  colony inhibition  has been confirmed  in 
some experiments in which treatment of patients' bone marrow cells with T  cell- 
specific mAb and complement restored colony-forming ability (23). 
The exact mechanism by which T  cells suppress colony formation is unknown. 
Zoumbos et  al.  (12)  have  shown  that  mitogen-activated  T  cells from  aplastic 
anemia patients produce levels of immune interferon (IFN-3") higher than those 
produced by T  cells from  healthy donors,  and  that  the  titers of IFN-3, in  the 
supernatants  correlate with  their ability to inhibit colony formation.  The same 
authors  (24)  also  reported  the  presence  of  IFN-2~ in  the  bone  marrow  and 
peripheral blood of patients with aplastic anemia, and proposed that activated T 
cells suppress granulocyte  precursors,  in  vivo as well as in vitro,  by release  of 
IFN-3'. Such a hypothesis is further supported by the observation that conditioned 
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medium (CM) ~ from  PHA-stimulated leukocytes from normal individuals con- 
tains colony-inhibiting activity (25,  26)  that is neutralized by antibodies against 
IFN-3`  (26).  Indeed, recombinant preparations of IFN3` have been shown (27- 
30)  to  inhibit colony formation  by  granulocyte and  monocyte precursor  cells 
(colony forming units of granulocytes and monocytes; CFU-GM).  However, we 
have observed (31)  that rIFN-3`, at concentrations corresponding to those nor- 
really present  in  PHA-CM,  is capable of only low  levels of inhibition of CFU- 
GM,  and  that  it  acts  synergistically with  recombinant  tumor  necrosis  factor 
(rTNF) to inhibit CFU-GM (31), indicating that other inhibitory factors produced 
by  activated  leukocytes  may  act  together  with  IFN-3`.  TNF  is  a  cytotoxin 
produced by activated myeloid or monocyte/macrophage cells (32,  33), and has 
biological and antigenic similarities with  the  colony-inhibiting activity that  we 
reported (31)  to be produced by NK cells upon  interaction with bone marrow 
cells.  Like its effect on bone  marrow, antiproliferative and cytotoxic effects of 
TNF on cell lines are also synergistic with IFN-3` (34). Human lymphotoxin (LT) 
is a  cytotoxin released by activated lymphocytes and present  in  PHA-CM  (35, 
36).  LT  has  28%  homology  in  amino  acid  sequence  to  TNF,  and  the  two 
cytotoxins share many biological activities (32). Analogous to the synergy of IFN- 
3' with TNF or NK colony-inhibiting activity the antiproliferative effect of LT 
on tumor cell lines is enhanced by the addition of 1FN-3` (37-40). 
In this paper, we discuss the effect of PHA-CM on colony formation, and show 
that  PHA-activated  purified  T  cells  produce  both  IFN-3`  and  LT.  which,  to- 
gether, inhibit colony formation by granulocyte and monocyte precursor cells. 
Materials and Methods 
Cell Lines.  Murine L-929 cells (alpha subline),  the human B lymphoblastoid cell line 
RPMI-8866 and the antibody-producing hybrid cell clones were maintained in  RPMI- 
1640 culture medium (Flow Laboratories, Rockville,  MD) supplemented with 10% FCS 
(Flow Laboratories). 
Monoclonal Antibodies.  Antibody OKT3, which reacts with all mature peripheral  T 
cells (41), was used as supernatant from hybrid cells (American Type Culture Collection, 
Rockville, MD). Antibodies B133.1, B133.3, B133.5, and B133.7 (all IgGI) react specifi- 
cally with human IFN-T but not with IFN-a or -/3 (42). Ascites fluid from antibody B133.3, 
1.5 x  107 neutralizing U/ml, was diluted 1:200 for pretreatment (6 h, 4°C) of PHA-CM. 
Antibodies reacting with human LT (LTB, 5.5 x  10=neutralizing U/~,g) and human TNF 
(TNFD,  2.7  ×  103  neutralizing  U/ug)  were  kindly provided  by  Dr.  H.  M.  Shepard 
(Genentech, Inc., South San Francisco, CA) and used at concentrations of 5 #g/ml for 
pretreatment (6 h, 4°C) of PHA-CM. 
Recombinant IFN-y.  Purified human rIFN-?, produced in E. coli and having a titer of 
7  x  10 ? antiviral  U/rag,  was  kindly provided by  Dr. J.  C.  Sevastopoulos and  H.  M. 
Shepard (Genentech, Inc.). Antiviral titer was periodically assayed as previously described 
(31).  rIFN-? had no colony-stimulating activity on normal bone marrow cells nor  LT 
activity on L-929 cells. 
Bone Marrow Cell Preparations.  Fragments of rib bone marrow, which are routinely 
removed during thoracic surgery (kindly provided by Dr. P. Addonizio, Dept. of Surgery, 
University of Pennsylvania, Philadelphia, PA), were collected in sterile RPMI-I 0% FCS. 
The specimen  was sequentially flushed with medium through  18-, 23-,  and  27-gauge 
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needles,  and  mononuclear cells  were  isolated  on  Ficoll/Hypaque (F/H)  (1.077  +_  0.01 
g/ml; Lymphoprep, Nyegaard and Co., Oslo, Norway) density gradient centrifugation. 
Bone Marrow  Colonies.  The  assay  for CFU-GM  was  a  modification of the  method 
described by Pike and Robinson (43).  Medium conditioned by the human monocyte-like 
cell line GCT (giant cell tumor) (Gibco, Grand Island, NY) was used as a source of colony- 
stimulating activity (44). GCT-CM contained neither IFN-% as measured by radioimmu- 
noassay (RIA), nor LT, as measured on L-929 cells. Mononuclear bone marrow cells were 
suspended (10  "~ cells/ml) in supplemented McCoy's medium (Gibco) containing 15% FCS, 
0.3% agar (Difco Laboratories, Detroit, M1), and  10% GCT-CM (unless indicated other- 
wise), and  1-ml aliquots were seeded into 35-mm Petri dishes (Flow Laboratories). Dishes 
were cuhured at  37°C in a  humidified 7%  CO2 incubator and the colonies (aggregates 
containing >40 cells) were counted at days 7 and 14 of culture. The colonies present after 
7 d of culture are derived from more mature GM precursor cells (late  CFU-GM), while 
those present after 14 days are derived from more primitive cells (early CFU-GM) (45). 
All experiments  were performed in  triplicate,  and the same lots  of FCS and GCT-CM 
were used throughout. Inhibition of CFU-GM by PHA-CM, by its fractions prepared as 
described below, or by lymphokines was tested by adding, at the time of seeding,  100/tl 
of medium containing the inhibitors to 1-ml aliquots of bone marrow cell suspension, and 
comparing the number of day 7 and day 14 CFU-GM to control plates.  The presence of 
colony-stimulating activity was assayed by adding  100 ul  of PHA-CM or its fractions to 
bone marrow cell cultures in the absence of GCT-CM. 
Preparation of Peripheral Blood Cells.  Peripheral blood was obtained by venipuncture 
from  healthy  donors and  anticoagulated  with  preservative-free  heparin.  Mononuclear 
cells were isolated using F/H density gradient centrifugation. Adherent cells were removed 
by  two  steps  of adherence  to  plastic  (45  rain  at  37°C)  to  obtain  nonadherent  PBL. 
Adherent cells  were  collected by scraping the  plastic  flasks  with  a  rubber  policeman. 
OKT3 + and OKT3- lymphocytes were obtained by indirect rosetting of OKT3-sensitized 
PBL with CrC13-treated,  goat anti-mouse Ig-coated sheep erythrocytes (E), followed by 
separation on an F/H gradient, as previously described (46,  47). 
Preparation of PHA-CM.  Peripheral  blood mononuclear cells or purified lymphocyte 
subsets  were cultured at a  concentration of 2  x  106 cells/ml in  RPMI-1640 containing 
1%  FCS and  1%  PHA (Wellcome Diagnostics,  Dartford, England) for 4 d at 37°C, in a 
humidified atmosphere of 5% CO2 in air. Autologous adherent cells were added at a final 
concentration of 105 cells/ml, where indicated. Cell-free supernatants were collected and 
stored at 4°C until use. 
Absorption of lFN-T from PHA-CM.  mAb B133.1, B133.3, B133.5, and B133.7, react- 
ing with  different  epitopes  of human  IFN-"F (42),  were  conjugated to  CNBr-activated 
Sepharose  4  B beads  (Pharmacia  Fine  Chemicals,  Uppsala,  Sweden) (50%  ammonium 
sulfate precipitate, 5 mg/ml gel). IFN--y was absorbed from PHA-CM by repeated mixing 
of PHA-CM with the antibody-coated Sepharose beads for 2 h at 4°C. In all experiments, 
the  IFN-'7-dep[eted PHA-CM contained  <1.5  U/ml  of IFN-~ as  measured  with  RIA 
described below. 
Chromatographic Fractionation of PHA-CM.  PHA-CM was concentrated 100-fold by an 
Amicon  8050  stirred  cell  equipped  with  a  PM-10  membrane  (Amicon  Corporation, 
Danvers, MA). 2-ml samples  were applied to a Sephadex G-100 (Pharmacia Fine Chemi- 
cals) column with  a  bed  volume of 400  ml,  and eluted  with  0.1%  PEG  8,000 (Fisher 
Scientific,  Fair Lawn, NJ) in  PBS, pH 7.4, at a flow rate of 40 ml/h.  24  10-ml fractions 
were eluted in the molecular weight range between  10,000 and  160,000, supplemented 
with  10% FCS, dialyzed twice against PBS, pH 7.4, once against RPMI-1640, and sterile- 
filtered.  Molecular  weight  markers,  run  on  the  column  under  identical  conditions, 
included IgG (158,000), BSA (67,000), ovalbumin (44,000), and myoglobin (17,000) (Bio- 
Rad Laboratories, Richmond, CA). 
Production  and  Purification  of Human  LT.  RPMI-8866  cells  were  suspended  (106 
cells/ml)  in serum-free RPMI containing 100 ng/ml of phorbol-12,13-dibutyrate (PdBU) 
(C.C.R., Inc., Eden Prairie, NM) and incubated at 37°C, 5% CO2 for 48 h. The cell-free 
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tridge (HIP 10-20; Amicon Corp., Danvers, MA) and a stirred cell  (PM  10 membrane; 
Amicon Corp.), and filtered through a  0.45 um filter (Nalge Co.,  Rochester,  NY).  The 
protein concentrate was dialyzed against 20 mM Tris HCI buffer, pH 7.8.  This buffer, 
and all other buffers used for purification, also contained 0.1%  PEG 8,000 and 0.1  mM 
PMSF (Sigma Chemical Co., St.  Lquis, MO). After dialysis,  the concentrate was applied 
to a  DEAE-Sepharose (Pharmacia Fine Chemicals) column. Elution was carried out with 
120 ml of a linear (0-0.4 M) NaCI gradient. LT-active fractions, determined by cytotox- 
icity on L-929 cells,  were pooled and applied to a lentil-lectin Sepharose 4 B (Pharmacia 
Fine Chemicals) column.  LT activity was eluted with  15  mM sodium phosphate buffer, 
pH  7.4,  containing  135  mM  NaC1 and  200  mM  c~-methylmannoside (Sigma Chemical 
Co.), dialyzed against 50 mM Tris-HCI buffer, pH 8.0, applied to a Blue-Sepharose CL-6 
B (Pharmacia  Fine Chemicals) column, and  eluted  with  50  mM  NaCl.  The eluate  was 
concentrated  10-fold by ultrafiltration (PM  10 membrane; Amicon Corp.), applied to an 
Ultragel AcA44 (LKB Instruments, Gaithersburg, MD) column and eluted with  15 mM 
sodium phosphate buffer, pH 7.4, containing  135  mM NaC1, at a flow rate of 15 ml/h. 
LT-active fractions were dialyzed against 20 mM Tris-HC1, pH 7.8, loaded on a Mono Q 
(Pharmacia Fine  Chemicals) column equipped on a  fast protein  liquid chromatography 
(FPLC) system (Pharmacia Fine Chemicals), and eluted with 10 ml of a linear (0-0.25  M) 
NaCI gradient. The resulting.protein was 200-fold purified with a 23% recovery of activity 
and had a final act of 8 x  105 U/rag protein. 
Assay  for LT Activity.  Serial dilutions of PHA-CM or fractions from the G-100 column 
were added to 3 x  104 mouse L-929 cells (alpha subline) per well in 96-well flat-bottomed 
microtiter plates in  the presence of 1 ~g/ml actinomycin D (Calbiochem-Behring Corp., 
San  Diego,  CA).  Cytotoxicity, identified  by rounding-up and detachment of cells,  was 
assessed microscopically after incubation for 24 h at 37 °C. The concentration (U/ml) of 
LT for each  sample was defined as  the  reciprocal of the dilution  that  produced  50% 
cytotoxicity. 
IFN-y RIA.  Antibody B133.5  was labeled with Na~25I (sp act  13-17  mCi/ug; Amer- 
sham Corp., Amersham, United Kingdom) using the chloramine T  method (48) (1  mCi 
~2~I per 20 ug protein). Antibody B133.1,  (5 •g/ml  in  0.1  M carbonate buffer, pH 9.5) 
was absorbed  (100  #l/well,  48  h  at  4°C)  to  96-well  vinyl  plates  (Serocluster;  Costar, 
Cambridge, MA). The plates were washed three times with cold PBS containing 0.05% 
Tween 20 (Bio-Rad Laboratories) (PBS-Tween), and  100 ~1 of test sample was added to 
triplicate  wells  and incubated  18  h  at 4°C.  Plates  were washed three  times with  PBS- 
Tween, 125I-labeled antibody B 13 B.5 was added (0.2 ug/ml, 100 ~l/wetl) to each well, and 
the plates were incubated  18 h at 4°C. The plates were then washed six times with cold 
PBS-Tween, dried, and the  well-bound radioactivity was measured in a  Packard Auto- 
Gamma 800 automated gamma counter (Packard Instrument Co., Downers Grove, IL). 
The IFN-y concentrations in the test samples were determined on the basis of a standard 
curve,  constructed  in  each experiment using a  laboratory standard  of purified natural 
human  IFN-y (Interferon Sciences,  New Brunswick,  NJ),  previously titered against the 
NIH 1FN-3~ standard Gg-23-901-530. The sensitivity of this RIA is 0.5 U/ml of IFN-y. 
Results 
Supernatants from PHA-stimulated Lymphocytes or T Cells Contain Both Stimulatory 
and Inhibitory  Activity  on CFU-GM.  As has been reported previously, PHA-CM 
contained  both  stimulatory  (3)  and  inhibitory  (25,  26)  activity  for  CFU-GM. 
PHA-CM  added  to  bone  marrow  cell  cultures  in  the  absence  of  GCT-CM 
displayed significant colony-stimulating activity for day 14 CFU-GM, but not for 
day 7  CFU-GM.  PHA added  at a  concentration  equal to  that present  in  PHA- 
CM showed no stimulation of colonies under these conditions.  Final concentra- 
tions of 10%  PHA-CM, added  to bone marrow cell cultures  in the presence of 
GCT-CM as a  source of colony-stimulating activity, inhibited day 7  CFU-GM by 
42-75%,  and significant inhibition  was observed at concentrations  of PHA-CM MURPHY  ET  AL.  267 
TABLE  I 
PHA-induced  Production of Colony-inhibiting and Colony-stimulating Activity, IFN-7, and LT 
by Pur~ed Populations of Peripheral Blood Mononuclear Cells 
Colony-inhibiting ac-  Colony-stimu- 
Adherent  tivity* (percent inhibi-  lating activity  i 
Cells cultured  cells  tion of CFU-GM) on:  (CFU-GM per  IFN-~. (U/ml)  LT (U/ml) 
added*  105 cells) on 
Day 7  Day 14  day 14 
Total PBL  No  38 ±  8  27 ± 9  25 ±  10  260 ± 57  12 ± 5 
Yes  46 + 7  2 +  19  46 ±  16  469 ± 231  20 ±  8 
OKT3 ÷ PBL  No  61 ± 7  43 +  14  52 ± 21  136 +  128  32 ± 0 
Yes  75 ±  14  22 + 23  71 ± 30  281  ±  184  44 ± 24 
OKT3- PBL  No  18+14  -4+11  22+9  59+--75  3+1 
Yes  18±5  -3+  10  33± 19  66±64  4± 1 
Adherent cells  No  5 +  5  -6 +  5  2 -  2  3 + 4  1 +  1 
Cells were cultured (2 X  l0  s cells/ml) in medium containing 1%  FCS and  1% PHA. After 4 d, 
supernatants were collected and tested for colony-inhibiting  and colony-stimulating activity, IFN- 
"y, and LT. All results are expressed as the mean + SD from four experiments. 
* A utologous adherent mononuclear cells were added (105 cells/ml) to cell cultures, where indicated. 
Supernatants were added (100/~l/dish) to bone marrow cultures in the presence of 10% GCT-CM. 
Percent inhibition was determined by comparing the number of colonies in test cultures to the 
number of colonies in control plates to which  100/~l/dish of culture medium was added. CFU-GM 
per 105 cells in control plates for day 7 and day 14 were 138 + 40 and 60 +  19, respectively. 
Colony-stimulating activity was determined by adding supernatants (100 ul/dish) to bone marrow 
cells in the absence of GCT-CM. 
as low as 1%. Inhibition of day  14 CFU-GM  ranged from  17 to 36%  when PHA- 
CM was present at  10%  final concentration. 
To  determine  which cell types produce  the inhibitory and stimulatory effects 
present in PHA-CM,  nonadherent  PBL from four donors were separated into T 
(OKT3 +) and  non-T  (OKT3-)  cells by indirect rosetting.  The  separated  popu- 
lations, with or without the addition of autologous adherent  cells, were cultured 
in the presence or absence of PHA  for 4  d, and  the cell-free supernatants  were 
assayed for stimulation or inhibition of day 7 and day 14 CFU-GM,  and for titers 
of IFN-'y and  LT  (Table  I).  Supernatants  from  separated  populations cultured 
for  4  d  in  the  absence  of  PHA  did  not  contain  significant  levels  of  colony- 
inhibiting or  colony-stimulating activity, or of IFN-7  or  LT  (data  not  shown). 
Upon  stimulation  with  PHA,  lymphocyte populations produced  all four of the 
activities measured,  although  there  was  variability in the amounts  produced  by 
different  donors.  Colony-stimulating acuvity,  which  was  active  only on  day  14 
CFU-GM,  was produced  by all lymphocyte populations. Adherent  cells alone did 
not produce  colony-stimulating activity, but when added to lymphocyte cultures, 
they enhanced  its production.  Supernatants  from  PHA-stimulated  OKT3 + PBL 
mediated  the  highest  levels of inhibition  of both  day  7  and  day  14  CFU-GM. 
The addition of autologous adherent  cells to cultures of PHA-stimulated OKT3 ÷ 
or total PBL resulted in increased ability of the supernatant  from the cultures to 
inhibit  day  7  CFU-GM,  but  decreased  its  ability  to  inhibit  day  14  CFU-GM. 
Supernatants  from  PHA-stimulated  OKT3-  PBL, either with  or without added 268  LYMPHOKINES  INHIBIT  HEMATOPOIETIC  COLONY FORMATION 
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FIGURE  1.  Effect of IFN-7-depletion on the ability of PHA-CM to inhibit day 7 CFU-GM. 
IFN-7 was absorbed from three separate PHA-CM preparations using anti-IFN-~ antibody- 
coated Sepharose. Culture medium, l0  s U/ml rIFN-% PHA-CM, and IFN-~,-depleted PHA- 
CM in the absence or presence of 103 U/ml rlFN-7, were added to bone marrow cells. Bars 
and error bars represent the mean and SD of triplicate cultures. 
adherent cells,  showed  low levels of inhibition  of day  7  CFU-GM  and  did  not 
inhibit day  14  CFU-GM.  IFN-y  was  produced  by all  lymphocyte populations, 
but  PHA-stimulated  total  PBL  produced  more  IFN-y  than  either  OKT3 + or 
OKT3-  PBL. LT activity was detected in supernatants from total PBL, and was 
two- to threefold enriched in supernatants from OKT3 + PBL. OKT3-  PBL and 
adherent cells produced very low or insignificant levels of LT. 
IFN-'y  Synergizes  with  Other  Factor(s)  Present  in  PHA-CM  to  Inhibit  CFU- 
GM.  IFN-y was absorbed by immunoaffinity chromatography from three dif- 
ferent preparations of PHA-CM, and the IFN-'r-depleted PHA-CM preparations 
were assayed for inhibition  of day 7  CFU-GM  with  or without the addition  of 
103  U/ml  rIFN-y  (Fig.  1).  The  final  concentration  of  103  U/ml  rIFN-y  is  in 
excess of the concentration present in bone marrow cultures when  10%  PHA- 
CM,  not depleted of IFN-y, is added.  The inhibition of CFU-GM  mediated by 
PHA-CM at  10% final concentration was completely abrogated after absorption 
of IFN-y  from  the  supernatants.  When  103  U/ml  rIFN-y  were  added  to  the 
cultures together with the IFN-y-depleted PHA-CM, the inhibition of CFU-GM 
was significantly higher than that caused by  103  U/ml rIFN-y alone, suggesting 
that IFN-y synergizes with another factor(s) present in PHA-CM to inhibit CFU- 
GM.  Synergy between  IFN-y and  IFN-y-depleted PHA-CM  is also observed at 
lower concentrations of IFN-y, which  show  very little inhibition  on  their own 
(Fig. 2). 
The Colony-inhibiting Activity  Present in PHA-CM Elutes from a Sephadex C-lO0 
Column in Fractions Containing Both IFN-y and LT Activities.  PHA-CM fractions 
obtained on a Sephadex G-100 column were assayed for inhibition and stimula- 
tion of CFU-GM,  IFN-y, and  LT activity. Fig.  3 illustrates the results from one 
such  fractionation,  representative  of four  experiments.  The  highest  levels  of 
inhibition  of day  7  CFU-GM  eluted  in  fractions corresponding to a  molecular 
weight range between 45,000 and 80,000 (Fig.  3A). Colony-stimulating activity MURPHY  ET  AL.  269 
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FIGURE 2.  Synergy between IFN-3" and IFN-3,-depleted PHA-CM in  CFU-GM inhibition. 
The indicated concentrations of rlFN-~' were added to bone marrow cells in the presence (0) 
or absence (O) of 100  #l/dish of IFN-3,-depleted PHA-CM. The data points represent the 
percent  inhibition as compared to  control plates, which  received  100  ~l/dish of culture 
medium. The number of day 7 CFU-GM per 105 cells in control plates was 167 +  35 (mean 
+ SD from three experiments). 
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FIGURE 3.  Sephadex  G-100  gel filtration of PHA-CM.  Each  fraction was  tested  for (A) 
number of day 7 CFU-GM when added to bone marrow cultures containing 10% GCT-CM 
as a source of colony-stimulating activity (C)), and number of day 14 CFU-GM colonies when 
added (100 ul/dish) to bone marrow cells in the absence of GCT-CM (0); (B) LT activity (["1), 
as measured by cytotoxicity of L-929 cells, and IFN-3, activity (A), as measured by RIA. Mol 
wt markers (×10 -s) are indicated by arrows. The number of day 7 CFU-GM in control plates 
in the presence of 10% GCT-CM was 195 + 2 (mean and SD of triplicate cultures). 
for  day  14  but  not  for  day  7  CFU-GM  eluted  in  a  molecular  weight  range 
between  10,000 and 30,000  (Fig. 3A). In some experiments, low levels of colony 
formation  or  cluster  formation  (<40  cells)  was  also  observed  when  fractions 
eluting in  higher  molecular weight ranges were  added  to cultures (not shown). 
The peak of IFN-3' activity eluted at 45,000 tool wt, while most of the LT activity 
was  eluted  in  fractions  with  a  molecular  weight  of 85,000-120,000  (Fig.  3B). 
Thus,  fractions  exerting  the  highest  levels of inhibition  do  not  coincide  with 
either the peak of IFN-3, or the peak of LT, but rather with fractions containing 
low levels of both activities. 
To determine  whether  CFU-GM  inhibition was due to synergism between the 270  LYMPHOKINES  INHIBIT  HEMATOPOIETIC  COLONY  FORMATION 
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FIC,  URE  4.  Inhibition of CFU-GM by Sephadex G-100 gel filtration fractions of PHA-CM in 
the presence of LT or rIFN-3'. Fractions were added to bone marrow cells (I00 gl/dish) alone 
(.4), in the presence of 10 U/m] purified LT (B), or with 103 U/ml rlFN-~ (C). CFU-GM were 
counted at day 7 of culture. LT (I-3) and IFN-3' (ZX)  activity in the fractions is shown in D. 
two  lymphokines, all  fractions  were tested  in  the presence of excess  LT  (10 
U/ml), purified from RPMI-8866 supernatants, or excess IFN-~ (10  ~ U/ml rIFN- 
y)  (Fig.  4).  If inhibition  requires  the  presence  of both  factors,  under  such 
conditions,  the inhibitory activity is  expected to coelute with  the lymphokine 
present at limiting levels. When excess LT was added to the cultures, the peak 
of colony-inhibition corresponded to the elution peak of IFN-3' (Fig.  4B), and 
likewise, when excess IFN-'/  was added,  the peak  of colony inhibition  corre- 
sponded to the elution peak of LT (Fig. 4C). Consistent with the results in Fig. 
3,  when fractions alone were added to the CFU-GM assay (Fig.  4A), the peak 
colony-inhibiting activity was present in fractions containing both IFN-'r and LT 
(Fig. 4D). 
mAb against IFN-3, and LT,  but not TNF,  Block PHA-CM-induced Inhibition  of 
CFU-GM.  Table  II  shows the results from experiments where four PHA-CM 
preparations were treated with mAb against IFN-'y, LT, or TNF, and then tested 
for their ability  to  inhibit  colony formation  by day  7  and day  14  CFU-GM. 
Incubation of PHA-CM with antibody against either IFN-y or LT abrogated its 
inhibitory activity, although a low level of inhibition of day 7 CFU-GM remained 
in some preparations after treatment with anti-LT antibody. Antibody against 
TNF  did  not abolish  inhibition.  Identical results  were obtained  using the gel 
filtration  fractions  of PHA-CM  that  showed  the  highest  CFU-GM  inhibiting MURPHY  ET  AL.  271 
TABLE  II 
Effect of mAb against IFN-'y (B133.3), LT (LTB), and TNF (TNFD) on Colony-inhibiting 
Activity of PHA-CM 
Day 7 CFU-GM per 10 ~ cells  Day 14 CFU-GM per l0  s cells 
Exp.  PHA-CM pretreatment  ~  PHA-CM pretreatment 
Medium*  Medium 
None  B133.3  LTB  TNFD  None  B133.3  LTB  TNFD 
1  156  47  156  120  50  61  43  75  62  48 
2  126  69  127  117  75  54  35  58  56  37 
3  179  104  161  171  ND  74  47  68  73  ND 
4  175  45  181  ND  ND  59  49  91  ND  ND 
Numbers are mean numbers of CFU-GM from triplicate plates. Standard deviations for triplicate 
plates were always less than five. 
* Control plates received 100/~1 per dish of culture medium. 
PHA-CM was incubated (6 h, 4°C) alone or with B133.3 (ascites fluid, 1:200),  LTB (5 ~tg/ml), or 
TNFD (5/xg/ml) before being added (100 ~l/dish) to bone marrow cells. 
activity (not shown).  The  antibodies,  when added alone to bone marrow  cells, 
did not affect the number of colonies produced (not shown). 
Purified LT and Recombinant IFN-3, Synergize  to Inhibit Day 7 and Day 14 CFU- 
GM.  To determine whether the synergy between LT and IFN-'y is sufficient to 
explain  the  strong  inhibition  of CFU-GM  mediated  by  PHA-CM,  we  tested 
purified  preparations  of  LT  and  rIFN-'y  for  their  ability  to  inhibit  colony 
formation.  The purified LT preparation  used in these experiments had asp act 
of 8 x  105 U/mg, as measured by cytotoxicity on L-929 cells, and its activity was 
abolished by the same mAb (LTB) that abrogated LT activity in PHA-CM (Table 
II).  Fig.  5  shows results  of an  experiment  in  which  various concentrations  of 
purified LT were added to bone marrow cells, either in the presence or absence 
of  103  U/ml  rIFN-3,.  LT  alone  at  concentrations  of 5  and  10  U/ml  exerted 
modest inhibition on day 7 CFU-GM, but did not inhibit day 14 CFU°GM even 
at  concentrations  of  10  U/ml  When  rIFN-3,  was  present  in  addition  to  LT, 
inhibition was greatly enhanced. Treatment of bone marrow cells with 103 U/ml 
rIFN-3,  alone produced  30%  inhibition  of day 7  CFU-GM; however, the com- 
bined effects of rIFN-3, and LT was more than additive for all LT concentrations 
tested. Neither  103 U/ml rIFN3, nor 10 U/ml of LT inhibited day 14 CFU-GM, 
but 65% inhibition was observed when the two factors were combined. 
Discussion 
Conditioned medium from mitogen-stimulated lymphocytes has been observed 
to contain colony-inhibiting (25, 26) and colony-stimulating activity (3, 49), IFN- 
~/(42, 50, 51), and LT (35). The cell separation experiments reported here show 
that OKT3 + lymphocytes (T cells), and not OKT3- lymphocytes (non-T cells) or 
adherent  mononuclear cells are the most effective producers of these activities 
upon PHA stimulation.  Mitogen-stimulated T  cells produced colony-stimulating 
activity for day  14  but  not for day 7  CFU-GM,  whereas the  colony-inhibiting 
activity present  in supernatants  of both T  and  non-T lymphocytes appeared to 
be most potent for the day 7 CFU-GM. The presence of granulocyte/macrophage 
colony stimulating  factors (GM-CSF) has been observed in  PHA-CM (49).  One 272  LYMPHOKINES  INHIBIT  HEMATOPOIETIC  COLONY  FORMATION 
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LT was added to bone marrow cultures at the indicated final concentrations either in the 
presence (0) or absence (O) of I 0  a U/ml rIFN-3,, and the number of colonies were counted at 
day 7 (A) and day  14 (B). The data represent  the percent  inhibition of colony formation 
determined by comparing the mean colony numbers of test cultures to those of  control cultures 
containing 100 t~l of culture medium. Error bars represent the standard deviation from three 
separate experiments, in which the number of colonies in control cultures were 231 -+  122 
day 7 CFU-GM per 105 cells, and 67 + 20 day 14 CFU-GM per 105 cells. 
type of GM-CSF, GM-CSFa, which stimulates colony formation by day 14 CFU- 
GM  (52),  is  probably  responsible  for  the  colony-stimulating  activity  present 
in our supernatants.  Despite the presence of colony-stimulating activity for day 
14 CFU-GM, supernatants from PHA-stimulated T  cells inhibited day  14 CFU- 
GM in the presence of 10% GCT-CM, suggesting that the inhibitory substances 
released by T  cells override the influences of CSF, and are therefore the more 
potent regulators of GM colony formation contained in supernatants from PHA- 
stimulated T  cells. Supernatants from mitogen-stimulated non-T  cells (predom- 
inantly  B  and  NK  cells)  contained  very  low  levels  of LT  and  approximately 
threefold less  IFN--y than  did T  cell supernatants;  they did not inhibit day  14 
CFU-GM, and only poorly inhibited day 7 CFU-GM.  The IFN-3, present in the 
non-T  lymphocyte supernatants may be a product of NK cells, whicb have been 
shown to produce IFN-3' upon stimulation with PHA (53) or IL-2 (42). Produc- 
tion of IFN-3, by NK cells after stimulation by PHA or T  cell-derived IL-2 might 
also explain  the higher titers of IFN-3' present in supernatants  from total  PBL 
than in supernatants from purified T  cells. 
The inability of IFN-3,-depleted  PHA-CM  to inhibit colony formation shows 
that  IFN-'y is essential  for PHA-CM-induced  inhibition  of CFU-GM.  However, 
IFN-3' alone  is  not sufficient to explain  the  potent inhibition caused  by PHA- 
CM.  As shown in Figs.  1 and  2,  l0 s U/ml  of rIFN-2/, a  concentration of IFN-3~ 
~20-fold higher than that present in cultures containing 10% PHA-CM inhibits 
colonies significantly less than either 10% PHA-CM or IFN-'y-depleted PHA-CM 
to which  103  U/ml  of rIFN-3'  was added.  These data  suggest  that  IFN-3' acts 
together with other factor(s) present in PHA-CM to inhibit CFU-GM. 
Our observation that IFN-'r alone mediates only minimal  inhibition of CFU- MURPHY ET  AL.  273 
GM contrasts with other studies (26-30,  54) in which strong inhibition of CFU- 
GM by |FN-3~ was reported. The purified preparations of natural  IFN-3' used in 
early studies (26, 54) may have contained contaminating  LT, as shown by Stone- 
Wolff et  al.  (38),  in  amounts  sufficient  to  synergize  with  IFN-~  in  inhibiting 
CFU-GM. The ability of antibodies against IFN-3, to completely block CFU-GM 
inhibition  by  IFN-3'  preparations  (54)  does  not  rule  out  the  possibility  that 
contaminating LT is also responsible for inhibition, as we have observed complete 
abrogation of inhibition by LT-containing  PHA-CM using an mAb against IFN- 
3'.  More  recent  reports  (27-30)  show  that  purified,  homogeneous rIFN-%  at 
concentrations lower than  those used in this report,  is still  capable of inhibiting 
CFU-GM, although  to  a  lower degree  than  was shown  using  purified  natural 
IFN-% We attribute the differences with our results to the different source and 
concentration of colony-stimulating activity, especially when using PHA-CM (28) 
or human  placental-conditioned  medium  (29),  which  may also contain  LT  or 
TNF.  The  colony-stimulating activity (GCT-CM)  used in  our experiments did 
not contain IFN-3, or LT activity, as measured by RIA or cytotoxicity on L-929 
cells,  respectively.  Differences  in  the  methods  used  for  purification  of bone 
marrow cells have also been shown to influence the sensitivity of precursor cells 
to IFN-'r (55), and may explain the difference between our results and those of 
Griffin et al. (27) who report 58% inhibition of day 14 CFU-GM with 500 U/ml 
of rIFN-3' using partially purified progenitor cell preparations. 
Fractionation of PHA-CM revealed that the fractions most active in inhibiting 
CFU-GM were those corresponding  to mol wt between 45,000 and  80,000,  in 
which botb IFN-~ and LT activity were present.  IFN-'y eluted in a broad peak 
of mol wt between 30,000 and 70,000, with the highest levels of activity eluting 
at  tool wt of ~45,000.  This  tool  wt is consistent  with  other  measurements  of 
IFN-3, by gel filtration (56). The peak LT activity eluted in the range of 85,000- 
120,000  tool wt.  Analysis of LT by gel filtration  has shown  molecular  weight 
heterogeneity of the LT molecule (57,  58), probably due to a  strong tendency 
ofa monomeric 25,000 mol wt form to aggregate into polymers (59). The elution 
pattern observed in our fractionations is consistent with that of c~-LT described 
by Granger et al. (57). We also observed low levels of LT activity in the tool wt 
range of 50,000-65,000, which is similar to the LT partially purified from PHA- 
CM by Stone-Wolff et al. (38), or with the LT purified from supernatants of the 
B  lymphoblastoid  cell  line  RPMI-1788  (36,  60).  Although  variability  among 
different  PHA-CM  preparations  was  also  observed  for  the  titers  of  ]FN-'y 
produced,  the peak of colony-inhibiting activity always eluted in  fractions con- 
taining  low levels of both  IFN-3,  and  LT.  This  elution  pattern  suggested  that 
both IFN-~ and LT are necessary for inhibition of CFU-GM. The results of the 
experiments in which excess LT or excess IFN-3' was added to PHA-CM fractions 
supports  the conclusion  that  inhibition  of CFU-GM is observed wherever ade- 
quate amounts of both activities are present.  The ability of mAb against either 
LT  or  IFN-3,  to  almost  completely  abrogate  PHA-CM-induced  inhibition  of 
CFU-GM establishes that both LT and IFN-3' are required for this activity. The 
low level of inhibition remaining in some supernatants after treatment with anti- 
LT antibody could be attributed  to IFN-3' alone, which at high  concentrations 
is capable of inhibiting day 7 CFU-GM (Figs.  1 and 2).  Anti-TNF antibody had 274  LYMPHOKINES  INHIBIT  HEMATOPOIET1C COLONY FORMATION 
no effect on inhibition, indicating that LT and not TNF, a cytokine that we have 
previously shown to inhibit  CFU-GM (31), and  which may be produced by the 
monocytes or NK cells present in the mononuclear cell preparations  (38, 61), is 
responsible  for  the  CFU-GM  inhibition  mediated  by PHA-CM.  The  negative 
results obtained with the anti-TNF antibody cannot be attributed to inactivity of 
the  antibody,  because  the  same  preparations  of  antibody  were  effective  in 
abrogating the colony-inhibiting activity of NK cell-derived supernatants  (31). 
We used rIFN-'y and purified LT preparations  to show that these two factors 
together are capable of strong  inhibition  of CFU-GM in  the absence of other 
factors that  might  be present  in  PHA-CM.  Like  IFN-3,,  LT is capable of only 
minimal  inhibition  of day 7 CFU-GM at concentrations (10 U/ml) in excess of 
those present when  10% PHA-CM is added to bone marrow cells. However, LT, 
at concentrations  as low as 0.6  U/ml,  when added  together  with  103  U/ml of 
rIFN-%  showed  significant  inhibition  of  both  day  7  and  day  14  CFU-GM. 
Unfractionated PHA-CM preparations did not strongly inhibit day 14 CFU-GM, 
probably due  to  colony-stimulating  activity for day  14  CFU-GM contained  in 
PHA-CM. This interpretation is supported by the observations that supernatants 
from  PHA-stimulated lymphocytes produced in  the presence of adherent  cells 
contain  more colony-stimulating activity (6,  62) and  less inhibitory  activity for 
day  14  CFU-GM  than  supernatants  produced  without  added  adherent  cells. 
Conversely, gel  filtration  fractions  containing  LT and  IFN-%  but not colony- 
stimulating activity strongly inhibit both day 7 and day 14 CFU-GM. Thus,  the 
low levels of LT contained in PHA-CM, acting together with IFN-'y, are sufficient 
to explain the PHA-CM-induced inhibition of both day 7 and day 14 CFU-GM. 
The  mechanism  by which  IFN-'f and  LT act together to inhibit  CFU-GM is 
unknown. Studies of the synergistic interaction between these two factors on the 
cytotoxicity of cell lines have shown that the cytostatic or cytotoxic effects of LT 
are enhanced when target cells are pretreated with IFN-'r (39), suggesting that 
IFN-y may act by priming  the  target  cells to the effect of LT.  The  increased 
sensitivity of IFN-treated target cells to LT or TNF may be due to the ability of 
IFN-y to increase the number of receptors for these cytokines (63, 64). A similar 
mechanism may be operative on granulocyte and monocyte precursor cells. Our 
data, however, do not exclude the possibility that IFN-'y and/or LT act indirectly 
on precursor  cells through  other  bone  marrow  cell  types that  might  regulate 
precursor cell growth. 
LT and  TNF  share  the ability to induce  tumor  necrosis and  cytotoxicity of 
cell lines (60);  however, our data indicate that  they may not behave identically 
in their colony-inhibiting activities. We have previously reported (31) that rTNF, 
at the same low concentrations  used for LT in these experiments,  is capable of 
significant inhibition of day 14 CFU-GM in the absence of IFN-3,. In the present 
experiments, purified LT had very little colony-inhibiting activity in the absence 
of IFN-3,.  Equivalent  concentrations  of LT and  TNF,  however, are capable of 
synergizing  with  IFN-'y to inhibit  day 7 CFU-GM.  These distinct properties of 
LT and  TNF probably do not depend on variability in sensitivity to cytokines 
among  bone  marrow  donors,  because  the  same  effects were  observed  when 
purified LT and rTNF were simultaneously tested for colony-inhibiting activity. 
We have shown that activated T  cells produce a variety of soluble factors that, MURPHY  ET  AL.  275 
together, influence the growth and differentiation of granulocyte and monocyte 
precursor cells.  We have also identified a mechanism whereby activated T  cells, 
associated with certain forms of bone marrow failure, might suppress  hemato- 
poiesis through the simultaneous release of IFN-y and LT. 
Summary 
We have shown that lymphocytes stimulated by PHA produce colony-forming 
unit of granulocyte/monocyte (CFU-GM)-stimulating and -inhibiting activities, 
IFN-% and lymphotoxin (LT). IFN-7 is necessary for inhibition of CFU-GM by 
PHA-conditioned medium (CM),  as shown by experiments in which removal of 
IFN-y  from  PHA-CM  abrogated  inhibition.  However,  experiments  in  which 
rIFN-y was added to IFN-y-depleted PHA-CM revealed the presence, in PHA- 
CM,  of  other  factors  that  act  in  synergy  with  IFN-y  to  inhibit  CFU-GM. 
Fractionation of PHA-CM on a  Sephadex G-100  column was used to separate 
IFN-3' and LT. Colony-inhibiting activity was eluted in fractions that contained 
both  IFN-y and LT activities, identifying LT as a  factor present in  PHA-CM 
that  synergizes with  IFN-y to  inhibit CFU-GM.  Treatment of PHA-CM  with 
mAb against either  IFN-y or  LT  completely abrogated the  colony-inhibiting 
activity, demonstrating a requirement for both lymphokines in PHA-CM-induced 
inhibition of CFU-GM. Experiments using rIFN-y and preparations of purified 
LT confirmed that neither lymphokine alone, when added to bone marrow cells 
at the concentrations present in  PHA-CM, strongly inhibited day 7  or day  14 
CFU-GM, but that the two lymphokines, added together, behaved synergistically 
to  inhibit  CFU-GM  by  up  to  70%.  The  inhibition  observed  using  purified 
preparations  of lymphokines shows  that  synergy between  IFN-y  and  LT  is 
sufficient to  explain  PHA-CM-induced  inhibition  of CFU-GM.  Our  findings 
suggest  that  activated  T  cells  regulate  hematopoiesis  through  the  release  of 
inhibitory as well as stimulatory factors, and that the simultaneous production of 
IFN-~,  and LT may represent a  mechanism of suppression of hematopoiesis in 
the cases  of bone  marrow failure associated with the presence  of activated T 
cells. 
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